AKEBIA THERAPEUTICS, INC. Operating Cash Flow
AKEBIA THERAPEUTICS, INC. (AKBA) reported Operating Cash Flow of -$17.68 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-05
- AKEBIA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was $3.52M, a 84.22% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$21.21M.
- AKEBIA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $31.13M.
- AKEBIA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was $28.11M.
- AKEBIA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2025 was $67.99M.
- AKEBIA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$40.66M.
- AKEBIA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$23.38M.
- AKEBIA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$73.15M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$17.68M 10-Q · filed 2026-08-05 | $13.45M derived: sum of 3 quarters · filed 2026-08-05 | $41.55M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$21.21M 10-Q · filed 2026-05-07 | $9.92M derived: sum of 2 quarters · filed 2026-05-07 | $38.03M derived: sum of 3 quarters · filed 2026-05-07 | $60.37M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $31.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $59.23M derived: sum of 2 quarters · filed 2026-02-26 | $81.58M derived: sum of 3 quarters · filed 2026-08-05 | $67.99M 10-K · filed 2026-02-26 |
| 2025-09-30 | $28.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $50.45M derived: sum of 2 quarters · filed 2026-08-05 | $36.86M 10-Q · filed 2025-11-10 | $32.40M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $22.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $8.76M 10-Q · filed 2026-08-05 | $4.29M derived: sum of 3 quarters · filed 2026-08-05 | -$2.40M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$13.59M 10-Q · filed 2026-05-07 | -$18.05M derived: sum of 2 quarters · filed 2026-05-07 | -$24.75M derived: sum of 3 quarters · filed 2026-05-07 | -$34.81M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$4.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$11.16M derived: sum of 2 quarters · filed 2026-02-26 | -$21.23M derived: sum of 3 quarters · filed 2026-02-26 | -$40.66M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$6.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$16.76M derived: sum of 2 quarters · filed 2025-11-10 | -$36.19M 10-Q · filed 2025-11-10 | -$38.50M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$10.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$29.50M 10-Q · filed 2025-08-07 | -$31.81M derived: sum of 3 quarters · filed 2026-02-26 | -$38.97M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$19.43M 10-Q · filed 2025-05-08 | -$21.74M derived: sum of 2 quarters · filed 2026-02-26 | -$28.91M derived: sum of 3 quarters · filed 2026-02-26 | -$25.28M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$2.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$9.47M derived: sum of 2 quarters · filed 2026-02-26 | -$5.85M derived: sum of 3 quarters · filed 2026-02-26 | -$23.38M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$7.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$3.54M derived: sum of 2 quarters · filed 2024-11-07 | -$21.08M 10-Q · filed 2024-11-07 | -$75.75M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $3.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$13.91M 10-Q · filed 2024-08-08 | -$68.59M derived: sum of 3 quarters · filed 2024-08-08 | -$34.78M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$17.54M 10-Q · filed 2024-05-09 | -$72.22M derived: sum of 2 quarters · filed 2024-05-09 | -$38.41M derived: sum of 3 quarters · filed 2024-05-09 | -$69.07M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$54.68M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$20.87M derived: sum of 2 quarters · filed 2024-03-14 | -$51.53M derived: sum of 3 quarters · filed 2024-03-14 | -$73.15M 10-K · filed 2024-03-14 |
| 2022-09-30 | $33.80M derived: 10-Q 9 month − 10-K/A 6 month · filed 2023-11-08 | $3.15M derived: sum of 2 quarters · filed 2023-11-08 | -$18.48M 10-Q · filed 2023-11-08 | -$81.28M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | -$30.66M derived: 10-K/A 6 month − 10-K/A 3 month · filed 2023-08-28 | -$52.28M 10-K/A · filed 2023-08-28 | -$115.09M derived: sum of 3 quarters · filed 2023-08-28 | -$171.36M derived: sum of 4 quarters · filed 2023-08-28 |
| 2022-03-31 | -$21.62M 10-K/A · filed 2023-08-28 | -$84.43M derived: sum of 2 quarters · filed 2023-08-28 | -$140.70M derived: sum of 3 quarters · filed 2023-08-28 | -$203.84M derived: sum of 4 quarters · filed 2023-08-28 |
| 2021-12-31 | -$62.81M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-08-28 | -$119.08M derived: sum of 2 quarters · filed 2023-08-28 | -$182.22M derived: sum of 3 quarters · filed 2023-08-28 | -$252.97M 10-K/A · filed 2023-08-28 |
| 2021-09-30 | -$56.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$119.41M derived: sum of 2 quarters · filed 2022-11-03 | -$190.16M 10-Q · filed 2022-11-03 | -$220.94M derived: sum of 4 quarters · filed 2023-08-28 |
| 2021-06-30 | -$63.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$133.89M 10-Q · filed 2022-08-04 | -$164.67M derived: sum of 3 quarters · filed 2023-08-28 | -$191.91M derived: sum of 4 quarters · filed 2023-08-28 |
| 2021-03-31 | -$70.75M 10-Q · filed 2022-05-09 | -$101.53M derived: sum of 2 quarters · filed 2023-08-28 | -$128.76M derived: sum of 3 quarters · filed 2023-08-28 | -$91.55M derived: sum of 4 quarters · filed 2023-08-28 |
| 2020-12-31 | -$30.78M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-08-28 | -$58.02M derived: sum of 2 quarters · filed 2023-08-28 | -$20.80M derived: sum of 3 quarters · filed 2023-08-28 | -$110.39M 10-K/A · filed 2023-08-28 |
| 2020-09-30 | -$27.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $9.98M derived: sum of 2 quarters · filed 2021-11-04 | -$79.61M 10-Q · filed 2021-11-04 | -$171.74M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $37.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$52.37M 10-Q · filed 2021-08-05 | -$144.50M derived: sum of 3 quarters · filed 2022-03-01 | -$133.51M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | -$89.59M 10-Q · filed 2021-05-10 | -$181.72M derived: sum of 2 quarters · filed 2022-03-01 | -$170.74M derived: sum of 3 quarters · filed 2022-03-01 | -$209.10M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | -$92.14M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$81.15M derived: sum of 2 quarters · filed 2022-03-01 | -$119.51M derived: sum of 3 quarters · filed 2022-03-01 | -$257.44M 10-K · filed 2022-03-01 |
| 2019-09-30 | $10.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$27.38M derived: sum of 2 quarters · filed 2020-11-05 | -$165.31M 10-Q · filed 2020-11-05 | -$239.00M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | -$38.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$176.29M 10-Q · filed 2020-08-10 | -$249.99M derived: sum of 3 quarters · filed 2021-02-25 | -$262.45M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | -$137.93M 10-Q · filed 2020-05-05 | -$211.63M derived: sum of 2 quarters · filed 2021-02-25 | -$224.09M derived: sum of 3 quarters · filed 2021-02-25 | -$215.09M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | -$73.70M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$86.16M derived: sum of 2 quarters · filed 2021-02-25 | -$77.16M derived: sum of 3 quarters · filed 2021-02-25 | -$97.49M 10-K · filed 2021-02-25 |
| 2018-09-30 | -$12.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$3.46M derived: sum of 2 quarters · filed 2019-11-12 | -$23.80M 10-Q · filed 2019-11-12 | -$40.17M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | $9.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$11.33M 10-Q · filed 2019-08-08 | -$27.71M derived: sum of 3 quarters · filed 2020-03-12 | -$82.33M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | -$20.33M 10-Q · filed 2019-05-09 | -$36.71M derived: sum of 2 quarters · filed 2020-03-12 | -$91.33M derived: sum of 3 quarters · filed 2020-03-12 | |
| 2017-12-31 | -$16.38M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$71.00M derived: sum of 2 quarters · filed 2020-03-12 | -$56.16M 10-K · filed 2020-03-12 | |
| 2017-09-30 | -$54.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$39.78M 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | $14.84M 10-Q · filed 2018-08-08 | |||
| 2016-12-31 | $57.91M 10-K · filed 2019-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |